Meriofert Set

Follicle‑Stimulating Hormone, Luteinising Hormone, the active ingredient in Meriofert Set, is a gonadotropin (biologic) presented as a sterile injectable solution for subcutaneous use. It treats infertility caused by anovulation and supports controlled ovarian stimulation in assisted reproductive technologies.

GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Set acts on the reproductive hormone pathway to restore or enhance ovarian function. - Anovulatory infertility: induces follicular development to achieve ovulation. - Assisted reproductive technology (IVF) cycles: provides controlled ovarian stimulation for oocyte retrieval. - Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore normal reproductive function.

Adverse reactions may occur with any gonadotropin therapy.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Mild ovarian hyperstimulation syndrome: abdominal discomfort and bloating. - Headache: mild to moderate intensity. - Nausea: occasional episodes. - Breast tenderness: mild.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, shortness of breath, and increased risk of thrombosis. - Ovarian torsion: acute pelvic pain requiring surgical intervention. - Allergic reaction: urticaria, angioedema, or anaphylaxis.

Careful patient assessment and monitoring are essential when using Meriofert Set. - Patient selection: assess for contraindications such as ovarian cysts or uncontrolled thyroid disease. - Monitoring: perform ultrasound and estradiol measurements to adjust dose and avoid OHSS. - Pregnancy testing: confirm non‑pregnant status before initiating therapy. - Concurrent medications: avoid estrogen‑containing products that may alter response. - Allergy assessment: discontinue if signs of hypersensitivity occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Set may interact with several agents that influence ovarian response or coagulation.

Major Interactions (Avoid): - GnRH agonists: may amplify response leading to severe OHSS. - Estrogen therapy: can increase risk of ovarian cyst formation. - Thyroid hormone excess: may potentiate ovarian response.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for thromboembolic events in OHSS. - Diuretics: may mask fluid retention signs. - Corticosteroids: may affect estradiol levels.